Prelude Capital Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Prelude Capital Management’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-430	Closed	-$112K	–	2304
2018 Q4	$112K	Buy	+430	New	+$86.5K	0.01%	897
2018 Q3	–	Sell	-469	Closed	-$111K	–	2127
2018 Q2	$111K	Buy	+469	New	+$137K	0.01%	889

Other funds holding EVLO

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Prelude Capital Management's EVLO Position: Q1 2019 in Review

Prelude Capital Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2019, closing a stake of 430 shares — an estimated $112K sold.

Prelude Capital Management first reported a position in EVLO in Q2 2018 and held it in 2 quarters. The position peaked at $112K in Q4 2018. 41 funds tracked by Wall St. Rank hold EVLO as of Q1 2019.

Prelude Capital Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Prelude Capital Management sold 430 Evelo Biosciences, Inc. Common Stock shares in Q1 2019, an estimated $112K.
Prelude Capital Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
Prelude Capital Management's Evelo Biosciences, Inc. Common Stock position peaked at $112K in Q4 2018.
41 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2019.

Based on Prelude Capital Management's 13F filing for Q1 2019, filed 15 May 2019.